Nonrenal clearance pathways such as drug metabolism are decreased in chronic kidney disease (CKD). Although the mechanism remains elusive, uremic toxin retention and an altered gut microbiota are suspected to influence cytochrome P450s (CYPs) contributing to the unpredictable pharmacokinetics in patients with CKD. We characterized dysbiosis and uremia in CKD to elucidate associations between CYP expression and CKD progression. Rats fed control or CKD-inducing adenine diet were subsequently studied at five time points over 42 days. CYP expression and activity were compared to alterations in the 1) plasma and liver metabolome and 2) gut bacterial microbiota. CYP3A2 and CYP2C11 were downregulated in CKD by ≥76% (p<0.001) concurrently with or slightly prior to CKD onset as defined by serum creatinine.
Introduction
In this study, we hypothesized that CKD would cause uremia and gut microbial changes detectable prior to downregulation of drug metabolizing enzymes. Bacterial alterations and metabolic changes have not been comprehensively studied with respect to altered drug metabolism throughout the temporal progression of CKD. To our knowledge, this is the first study to use metabolomics and 16S bacterial rRNA gene sequencing to investigate CYP expression and activity over CKD progression. Our study aims to characterize plasma and liver uremic toxins, the gut microbial composition and CYP expression and activity over the progression of CKD.
Materials & Methods

Animal Model & Study Design
Sixty-six male Wistar rats (150g) were obtained from Charles River Laboratories, Inc.
(Wilmington, MA) and randomized into six groups defined by time of euthanasia (day 0, 3, 7, 14, 28 and 42). Each time point consisted of six control and six CKD rats. Rats were housed with a same-group cage mate to minimize coprophagy alterations of the gut microbiota. Rats were given either 0.5% adenine supplemented chow to induce CKD or standard chow pair fed to match caloric intake. Rats were euthanized by isoflurane anesthetization followed by decapitation.
Blood was collected in heparinized tubes and liver was snap-frozen in liquid nitrogen. Caecal samples were obtained on a sterile, single culture swab (BD, Sparks, MD) touched to an open incision of the caecum. All samples were stored at -80°C until further analysis excluding the right kidneys which were stored in 10% formalin.
Disease Markers & Histology
Conventional CKD markers urea and creatinine were measured in rat plasma using standard methods by the Pathology and Laboratory Medicine group (PaLM, London, ON; www.lhsc.on.ca/palm/). Kidney tissue and histological images were prepared as previously described (17) . Light microscopy and photographs of prepared haematoxylin and eosin stained slides were obtained on a Leica DM1000 light microscope paired with a Leica DFC295 camera and Leica Application Suite v3.8.0 software.
Real-Time Polymerase Chain Reaction (PCR)
Total mRNA was extracted from rat liver, tested for purity and quantified using quantitative PCR with methods and validated primers as stated previously (9) . Gene expression was normalized to β-actin using the ∆∆CT method.
Western Blotting
Hepatic microsomal fractions were prepared by differential centrifugation as previously described (17) . Western blot analysis was performed as previously published with minor alterations (17) and all blots were completed in duplicate for both CYP3A2 and CYP2C11.
Enzymatic Activity
Enzymatic activity was analyzed by incubating microsomal fractions with testosterone, a known substrate of CYP3A2 and CYP2C11. Testosterone metabolites 6βOH-testosterone (CYP3A2) and 16αOH-testosterone (CYP2C11) were measured via mass spectrometry (MS) in a 96-well plate assay adapted from (17) . In a final volume of 75µL, 0.2mg/mL microsomal protein and reaction buffer (50mM potassium phosphate with 2mM MgCl 2 pH 7.4) was incubated with 1µL testosterone (Steraloids Inc., Newport, RI) at concentrations of 12.5, 25, 75, 200 and 400µM for 10 min at 37°C. All reactions were initiated with the addition of 1mM NADPH (Sigma Aldrich) and shaken at 37°C for 20 min before the reaction was terminated using 225µL ice-cold acetonitrile with 80ng/mL flurazepam internal standard (Cerilliant, Round Rock, TX). Plates were shaken, centrifuged at 4000×g for 10 min, supernatant diluted 5-fold with milliQ water.
Enzymatic products were separated on a Phenomenex Kinetex phenyl-hexyl column (1.7µm particle size, 50mm × 2.1 mm) maintained at 40°C in a Waters ACQUITY UPLC I-Class System (Milford, MA). Mobile phase flow was set to 0.5 ml/min and consisted of UPLC-grade water (A) and acetonitrile (B) both containing 0.1% formic acid with a gradient as follows: 0-0.5 mins, 25% B; 0.5-2 mins 25-35% B; 2-2.5 mins 35-80% B; 2.5-3.5 mins held at 80% B; 3.5 mins 25% B. Analytes were detected using quadrupole time-of-flight mass spectrometry (QTof/MS) on a Waters Xevo TM G2S-QTof/MS and Waters ACQUITY I-Class UPLC with parameters as previously described (17) . Mass-to-charge ratios for hydroxy testosterone were targeted (m/z = 305.2117) for quantification using QuanLynx v4.1 software. Michaelis-Menten curves were generated with GraphPad Prism (v6.0; GraphPad Software Inc., San Diego, CA).
Untargeted Metabolomics
Sample & Batch Preparation
Plasma and liver samples were prepared as previously described (18) with 3:1 ice-cold acetonitrile and 2.5µM chlorpropamide internal standard (Sigma Aldrich) then run on both the Waters ACQUITY UPLC HSS T3 (1.8µm particle size, 100 mm × 2.1 mm) reverse-phase liquid chromatography (RPLC) column and the Waters ACQUITY BEH Amide (1.7µm particle size, 100 mm × 2.1 mm) hydrophilic interaction liquid chromatography (HILIC) column. Supernatant was either diluted 5-fold in water for RPLC or directly injected for HILIC. Sample injection order was randomized, and a quality control sample made from pooled samples was run every ten injections. All samples were run in a single batch for each biological matrix and column.
Chromatography & Mass Spectrometry
Columns were maintained at 45°C and mobile phase flow set to 0.45 ml/min consisting of UPLCgrade water (A) and acetonitrile (B), both containing 0.1% formic acid. The RPLC anlysis was run as previously described (18) . The HILIC column followed a gradient of 0-0.5 mins 99% B;
0.5-6 mins 99-50% B; 6-8 mins 50-30% B; 8-8.5 mins 30-99% B. Samples were run separately in succession for both positive and negative electrospray ionization (ESI) modes on the UPLCQTof/MS instrument. Mass spectrometer source, method, calibration and other parameters were identical to those in (18) and data was collected by MassLynx v4.1 software (Waters).
Data Processing
Data processing for each run and ionization mode was performed separately in R studio (v3.2.3).
MassLynx data files were converted to mzData files using convert.waters.raw package v1.0 (github.com/stanstrup/convert.waters.raw). Pooled samples were used to find the optimal peak picking parameters, retention time corrections and grouping parameters with the isotopologue parameter optimization package v1.0.0 (github.com/rietho/IPO/blob/master/vignettes/IPO.Rmd).
The resulting parameters were inputted into the XCMS package v1.50.1 to pick appropriate peaks, integrate the area under the curve and replace zero values (19). The CAMERA package v1.32.0 was used to annotate possible isotopes and adducts (20). XCMS and CAMERA packages were used to integrate positive and negative ionization modes before normalizing to internal standard and applying a threshold of 30% variability of the quality control.
Metabolite Identification
The accurate monoisotopic mass (m/z) and fragmentation spectrum of each metabolite was used to identify metabolites via METLIN, MassBank or Human Metabolome Database (HMDB) (21).
Metabolites were identified in accordance with the reporting standards for metabolite identification (22).
In Vitro Assessment of Uremic Toxins on CYP3A4 Expression
Human hepatoma Huh7 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 100 IU/ml penicillin, and 100 µg/ml streptomycin and 2 mM Lglutamine. Cells were grown at confluence for 4 weeks prior to treatment to ensure adequate CYP3A4 expression levels (23 hours. An indoxyl sulfate concentration-response effect on CYP3A4 mRNA expression was generated using a concentration range of indoxyl sulfate found in normal and CKD patients (0 to 1000 µM) with 40 g/L human serum albumin (HSA, Lee Biosolutions, St. Louis, MO). Indoxyl sulfate was incubated in media containing 40 g/L HSA for 3 hours at 37°C to allow for plasma protein binding equilibration prior to cell treatment. Cell viability was assessed using the TACS 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously described (24).
Gut Microbial Sequencing
Illumina Sequencing
DNA was extracted from caecum swabs using the PowerSoil-96 Well DNA isolation kit from 
Data Processing
Paired reads, each 220bp long were processed with the Illumina_SOP protocol accessed through Github with minor convenience revisions (https://github.com/ggloor/miseq_bin). After demultiplexing, raw reads were overlapped with a minimum 30 nucleotides using Pandaseq (v2.5) (27) then filtered with in-house Perl and UNIX scripts to ensure exact barcode matching and primer matching with up to two allowable mismatches (28). OTUs were clustered at 97% identity using the uSearch (v7.0.1090) tool (29) and the most abundant sequence in the OUT was annotated via the mothur script (30) to search the Silva 16S rRNA gene reference database (Silva.nr_v119) (31, 32). In mothur, a bootstrap cut-off of 70% was used for taxonomical identification and redundancy. A total of 1199 OTUs were retained across all samples (Supplementary Table 2 ). In R studio (v3.2.3) the zCompositions (v1.0.3-1) package (33) was used for zero-replacement before data was centered-log ratio (clr) transformed for compatibility with downstream multivariate statistical analysis (34, 35).
Statistical Analysis
Disease Markers, Real-Time PCR, Western Blotting & Enzymatic Activity Assay
CYP measurements and disease markers urea and creatinine are presented as mean ± SEM and analyzed by 2-way ANOVA paired with Sidak's multiple comparisons test. *p < 0.05 compared to matching day control indicates significance.
Untargeted Metabolomics
MassLynx software and the EZInfo v2.0 package (Umetrics, Umeå, Sweden) were used to Significance (p<0.05) was required for both "Time" and "Disease" to retain the metabolite for comparison with multivariate and correlative analyses. Spearman correlations were conducted between each metabolite and the mRNA, protein or enzymatic activity levels of each enzyme.
Metabolomics datasets were matched by sample to the corresponding CYP dataset and correlation coefficients (r-values) manually filtered with high stringency (r > 0.65 or r < -0.65).
Metabolites that did not also satisfy univariate analysis were removed from the correlation subset.
Metabolites that did not satisfy multivariate analysis are indicated but retained to capture biologically relevant changes independent of magnitude.
Caecal Microbiota
Multivariate PCA was performed in EZInfo as described above for untargeted metabolomics excluding scaling. To evaluate univariate differences between CKD and control groups, the effect size and overlap for each bacterial taxonomic group was calculated for each time point individually using the R package ALDEx2 (v1.2.0) (bioconductor.org/packages/release/bioc/html/ALDEx2.html) (38, 39) . Severe thresholds were applied to both effect size (> 1.5 or < -1.5) and overlap (< 6.5%) for each bacterial abundance (39, 40) . Significance was defined as satisfying the effect size and overlap thresholds with 95%
confidence. Species and strain information were manually searched using the Targeted Loci
Nucleotide BLAST application through NCBI (blast.ncbi.nlm.nih.gov/Blast.cgi).
Results
Model of CKD Progression
CKD markers urea and creatinine both showed significant increase in CKD rat plasma by day 14
( Figure 1 A-B ). This increase continued to a 9-fold and 11-fold difference between CKD and control for urea and creatinine, respectively, on day 42. Kidney histology showed enlarged tubules, inflammation and fibrosis by day 14 through to day 42 ( Figure 1 C-H). Animal weights did not change between groups (Supplementary Table 3 ).
Hepatic CYP3A2 & CYP2C11 mRNA Expression over CKD Progression
CYP3A2 mRNA expression was minimally decreased on day 3, recovered on day 7, then declined substantially by day 14 (-83%, p<0.001) which persisted to day 42 (-99%, p<0.001) (Figure 2A ). CYP2C11 mRNA expression was unchanged on day 3 but largely increased in the control group on day 7 leaving CKD rats well below normal (-76%, p<0.001) ( Figure 2B ). On day 14 (-84%, p<0.001), day 28 (-96%, p<0.001), and day 42 (-98%, p<0.001) the CKD CYP2C11 mRNA expression was decreased in comparison to control.
Hepatic CYP3A2 & CYP2C11 Protein Expression over CKD Progression
Significant decreases in CYP3A2 protein expression were observed in CKD animals on day 14 (-63%, p<0.001), day 28 (-86%, p<0.001) and day 42 (-85%, p<0.01) ( Figure 2C ). CYP2C11
protein quantification also shows depletion in CKD but starting on day 7 (-42%, p<0.05) through to day 42 (-83%, p<0.001) ( Figure 2D ).
Hepatic CYP3A2 & CYP2C11 Enzymatic Activity over CKD Progression
CYP3A2 intrinsic activity in CKD rats decreased on day 3, recovered on day 7 and fell again 3.6-fold by day 14, 13-fold by day 28 and nearly 14-fold lower than controls by day 42 ( Figure 2E ).
The intrinsic activity of CYP2C11 showed a 4.6-fold difference between CKD and control as early as day 7 and up to 12.8-fold difference by day 42 ( Figure 2F ). Michaelis-Menten parameters are summarized (Table 1) .
Plasma & Liver Metabolomics
Untargeted metabolomics analysis was used to assess changes in metabolite composition.
Principal component analysis (PCA) clearly separated CKD and control for both rat plasma and liver samples ( Figure 3 ). Early disease stages are arbitrarily defined as day 3-14 and late stages days 28 and 42. R 2 and Q 2 parameters were used to accompany the interpretation of OPLS-DA plots ( Table 2) . Metabolites in rat plasma were well separated from control as early as day 3 when using RPLC ( Figure 3A ). Liver RPLC showed far less separation between control and CKD before day 28 ( Figure 3B ). The HILIC column showed separation back to day 7 except for poor Q 2 values on day 14 in both plasma and liver samples ( Figure 3 C-D).
CYP Enzymes & Uremic Toxins
After satisfying multivariate and univariate analysis, metabolites were correlated to CYP mRNA, protein and enzymatic activity. There were 204 unique m/z ratios identified across all four runs that correlated with either CYP3A2 or CYP2C11 (Supplementary Table 4 ). Of these 204 m/z ratios, 9 metabolites were identified at identification level 1 using purchased standards. These metabolites include: allantoin, L-carnitine, creatinine, 2,8-dihydroxyadenine, equol-4/7-Oglucuronide, 4-ethylphenyl sulfate, indoxyl sulfate, pantothenic acid (vitamin B5) and phenyl sulfate (Table 3) . Indoxyl sulfate, phenyl sulfate and 4-ethylphenyl sulfate had increased concentration (p<0.0001) on days 28 and 42 for both plasma and liver tissue (Figure 4 ).
Indoxyl Sulfate Downregulates Hepatic CYP3A4 Expression in vitro
To investigate the mechanism of CYP3A downregulation in CKD, human hepatoma Huh7 cells were treated with selected uremic toxins. As an initial proof-of-concept screen, concentrations of uremic toxins used were the highest reported in patients with CKD ( hour treatment at clinically relevant concentrations ( Figure 5C ).
Caecal Microbiota
To understand if the gut microbiota was changing in parallel with metabolite changes, nextgeneration Illumina sequencing was used to assess the bacterial composition of the caecum (Supplementary Table 2 ). Exploratory PCA ordination showed that the caecum samples had high ( Figure 7A ) with an increasing trend associated with disease progression. The second OTU from phylum Bacteroidetes and genus Parabacteroides showed a significant decrease in control rats over time ( Figure 7B ).
Discussion
The pharmacokinetics of many drugs are unpredictably altered in CKD, making these patients susceptible to adverse drug events. Hepatic CYPs play a crucial role in nonrenal drug clearance and alterations in these CYPs may contribute to pharmacokinetic changes observed in CKD. CYP downregulation has been associated with decreased renal clearance and consequent retention of uremic toxins in animal models of CKD. Mechanistic studies suggest the involvement of various pathways from pre-transcriptional regulation to direct inhibition by uremic toxins, inflammatory factors, and hormones (9-13, 42, 43) . Uremic toxins are also suggested to change the relative abundance of gut bacteria to favor uremic-toxin producing microbes and create a state of dysbiosis in CKD patients (44) . Changes in metabolite or toxin production as a consequence of the altered microbiota may exacerbate CKD progression and potentially CYP downregulation.
However, the pathophysiological factors of uremia and dysbiosis have yet to be evaluated temporally. In this manuscript, uremia and dysbiosis were characterized over CKD progression to identify potential causes of CYP downregulation.
CYP3A2 and CYP2C11 were both downregulated by CKD with respect to mRNA expression, protein expression, and enzymatic activity as previously observed (45) . These findings suggest these CYPs were initially influenced at the transcriptional level, consequently leading to altered protein expression and enzyme activity. Expression of CYP3A2 in control rats was stable throughout the study while expression started to decrease on day 14 in CKD rats. These observations suggest the removal, inhibition, or downregulation of a constitutive factor required for expression, potentially mediated by the increase in uremic toxins (46) . In contrast, control rats exhibited an increase in CYP2C11 expression as early as day 7 but this increase was not evident in CKD rats. Increased CYP2C11 expression over time has been described in healthy male juvenile rats, where it was suspected to reflect increased testosterone levels during puberty (46).
Furthermore, CKD has been associated with hypogonadism and testosterone deficiency (47).
CYP2C11 is also influenced by alterations in the normally cyclic levels of growth hormone (GH) where continuous GH release or loss of GH production will both downregulate CYP2C11 (48) .
The differing trends between CYP3A2 and CYP2C11 may be attributed to nuclear receptor differences. CYP2C11 is less dependent on hepatocyte nuclear factor 4 alpha induction, and CKD-induced receptor binding inhibition is less extensive for CYP2C11 than it is CYP3A2 (17, 49) . Alternatively, it is also possible that removal or inhibition of shared nuclear receptor PXR or reduced receptor binding of RNA polymerase II is affecting both enzymes but in different manners depending on substrate availability (9, 17) .
Plasma samples showed greater metabolomics separation in earlier stages of disease (days 3-14)
than liver samples. This suggests CKD first inflicts a uremic environment in the plasma before infiltrating the liver. Uremic changes also overlapped with the early changes in CYP3A2 and CYP2C11, supporting the hypothesis that uremic toxins are involved with CYP regulation.
Metabolites from each metabolomics run were subjected to correlation analysis with CYP3A2 or Gut derived uremic toxins that are potentially involved in CYP downregulation from this study include indoxyl sulfate, phenyl sulfate, 4-ethylphenyl sulfate, equol-4/7-O-glucournide and products of L-carnitine metabolism. Indoxyl sulfate and phenyl sulfate are two highly retained gut-derived uremic toxins (50, 51) both found in CKD patients and animal models (18, 52) .
Indoxyl sulfate and phenyl sulfate have been associated with altered drug metabolism both through transcriptional regulation (42) , and indoxyl sulfate as a direct inhibitor of CYP activity (13) . Thus, the identification and observed increase in concentration of indoxyl sulfate and phenyl sulfate in this study support their previously described roles in modifying CYP regulation in CKD (Figure 4) . Further, our in vitro studies using Huh7 human hepatoma cells showed indoxyl sulfate decreases CYP3A4 expression in a concentration dependent manner.
Interestingly, of the metabolites found by correlation to CYP3A2 or CYP2C11, the five metabolites that are associated with CYP downregulation in the literature are all gut-derived uremic toxins.
Indoxyl sulfate, phenyl sulfate and 4-ethylphenyl sulfate concentration all increase after day 28 when changes are simultaneously observed in the gut microbiota that was phylogenetically analyzed using 16S sequencing. This lends support to the idea that uremia may be driving the change in gut microbial abundance through a damaged gut wall (Figure 8 ) (44, 53) . The late and pronounced increase in gut-derived uremic toxins also suggests dysbiosis contributes to the exacerbation of uremia, likely adding to the uremic milieu by increasing the number of bacteria capable of uremic toxin production (44) . Multivariate analysis showed the microbiota was most significantly influenced by time (i.e. age) and secondarily by disease state. This correlation suggests that the microbiota changes caused by CKD induction are less profound than age- Assuming all rats were exposed to Turicibacter for the study duration, our findings suggest CKD animals are more susceptible to gut colonization by Turicibacter. Mandal, R., Aziat, F., Dong, E., Bouatra, S., Sinelnikov, I., Arndt, D., Xia, J., Liu, P., Yallou, F., Bjorndahl, T., Perez-Pineiro, R., Eisner, R., Allen, F., Neveu, V., Greiner, R., 
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